Efficacy and safety of chloroquine for treatment in patients with uncomplicated Plasmodium vivax infections in endemic countries (Q33695141)

28 July 2017

title

Efficacy and safety of chloroquine for treatment in patients with uncomplicated Plasmodium vivax infections in endemic countries (English)

1 reference

28 July 2017

0 references

0 references

Cho Naing

1

1 reference

28 July 2017

Kyan Aung

series ordinal

2

1 reference

28 July 2017

Daw-Khin Win

series ordinal

3

1 reference

28 July 2017

Mak Joon Wah

series ordinal

4

1 reference

28 July 2017

language of work or name

1 reference

20 September 2010

1 reference

Transactions of the Royal Society of Tropical Medicine and Hygiene

28 July 2017

published in

1 reference

28 July 2017

volume

104

1 reference

28 July 2017

issue

11

1 reference

28 July 2017

page(s)

695-705

1 reference

Focus on Plasmodium vivax

28 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2010.08.009

Vivax malaria: neglected and not benign

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2010.08.009

Effects of Plasmodium vivax malaria in pregnancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2010.08.009

Emergence of chloroquine-resistant Plasmodium vivax in Myanmar (Burma).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2010.08.009

Efficacy of chloroquine in the treatment of Plasmodium vivax malaria in Turkey

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2010.08.009

Chloroquine-resistant Plasmodium vivax malaria in Debre Zeit, Ethiopia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2010.08.009

Plasmodium vivax resistance to chloroquine in Madagascar: clinical efficacy and polymorphisms in pvmdr1 and pvcrt-o genes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2010.08.009

Therapeutic efficacy of chloroquine plus sulphadoxine/ pyrimethamine compared with monotherapy with either chloroquine or sulphadoxine/pyrimethamine in uncomplicated Plasmodium falciparum malaria in Laos

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2010.08.009

Therapeutic responses of Plasmodium vivax and P. falciparum to chloroquine, in an area of western India where P. vivax predominates.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2010.08.009

COMPARISON OF CHLOROQUINE, QUINACRINE (ATABRINE), AND QUININE IN THE TREATMENT OF ACUTE ATTACKS OF SPOROZOITE-INDUCED VIV AX MALARIA (CHESSON STRAIN).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2010.08.009

Hyperparasitaemia and low dosing are an important source of anti-malarial drug resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2010.08.009

Comparative efficacy of chloroquine and sulphadoxine--pyrimethamine in pregnant women and children: a meta-analysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2010.08.009

Artemisinin derivatives versus quinine in treating severe malaria in children: a systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2010.08.009

Treatment of malaria in the United States: a systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2010.08.009

A double-blind, randomized study of azithromycin compared to chloroquine for the treatment of Plasmodium vivax malaria in India.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2010.08.009

Efficacies of 5- and 14-day primaquine regimens in the prevention of relapses in Plasmodium vivax infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2010.08.009

Sulfadoxine-pyrimethamine plus artesunate compared with chloroquine for the treatment of vivax malaria in areas co-endemic for Plasmodium falciparum and P. vivax: a randomised non-inferiority trial in eastern Afghanistan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2010.08.009

Clinical efficacy of chloroquine versus artemether-lumefantrine for Plasmodium vivax treatment in Thailand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2010.08.009

Compliance with 14-day primaquine therapy for radical cure of vivax malaria--a randomized placebo-controlled trial comparing unsupervised with supervised treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2010.08.009

Sulfadoxine-pyrimethamine, chlorproguanil-dapsone, or chloroquine for the treatment of Plasmodium vivax malaria in Afghanistan and Pakistan: a randomized controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2010.08.009

A randomised trial of an eight-week, once weekly primaquine regimen to prevent relapse of plasmodium vivax in Northwest Frontier Province, Pakistan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2010.08.009

Chloroquine sensitivity of Plasmodium vivax in Thailand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2010.08.009

Artemisinin or chloroquine for blood stage Plasmodium vivax malaria in Vietnam

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2010.08.009

Therapeutic responses to different antimalarial drugs in vivax malaria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2010.08.009

Efficacy of a 14-day primaquine regimen in preventing relapses in patients with Plasmodium vivax malaria in Mumbai, India

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2010.08.009

Randomized controlled trials of 5- and 14-days primaquine therapy against relapses of vivax malaria in an Afghan refugee settlement in Pakistan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2010.08.009

Randomized trial of 3-dose regimens of tafenoquine (WR238605) versus low-dose primaquine for preventing Plasmodium vivax malaria relapse

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2010.08.009

Radical curative efficacy of five-day regimen of primaquine for treatment of Plasmodium vivax malaria in India

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2010.08.009

Low efficacy of amodiaquine or chloroquine plus sulfadoxine-pyrimethamine against Plasmodium falciparum and P. vivax malaria in Papua New Guinea.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2010.08.009

Chloroquine-resistant Plasmodium vivax in transmigration settlements of West Kalimantan, Indonesia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2010.08.009

Plasmodium vivax resistance to chloroquine in Dawei, southern Myanmar

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2010.08.009

Development of resistance to chloroquine by Plasmodium vivax in Myanmar

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2010.08.009

Resistance to chloroquine by Plasmodium vivax at Alor in the Lesser Sundas Archipelago in eastern Indonesia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2010.08.009

Therapeutic responses to antimalarial and antibacterial drugs in vivax malaria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2010.08.009

Triangular test applied to the clinical trial of azithromycin against relapses in Plasmodium vivax infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2010.08.009

Therapeutic efficacies of artesunate-sulfadoxine-pyrimethamine and chloroquine-sulfadoxine-pyrimethamine in vivax malaria pilot studies: relationship to Plasmodium vivax dhfr mutations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2010.08.009

Diagnosis of resistance to chloroquine by Plasmodium vivax: timing of recurrence and whole blood chloroquine levels.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2010.08.009

Resistance to therapies for infection by Plasmodium vivax

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2010.08.009

A systematic overview of published antimalarial drug trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2010.08.009

Some considerations in the design and interpretation of antimalarial drug trials in uncomplicated falciparum malaria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2010.08.009

10.1016/J.TRSTMH.2010.08.009

7 January 2021

Identifiers

DOI

1 reference

28 July 2017

1 reference